First-In-Human Single and Multiple Ascending Dose Trial Design of LY3962681, a Novel Intrathecally Delivered siRNA Targeting α-synuclein mRNA for the Treatment of Patients with Parkinson’s Disease
Objective: Development of a Phase 1 clinical trial evaluating LY3962681, a novel, intrathecally delivered siRNA directly targeting α-synucleinmRNA (SNCA) to reduce α-synuclein protein (ASYN), for the treatment of…Efficacy of Novel A2A/A1 Antagonist in Motor and non-Motor Symptoms of MPTP-Treated Macaques
Objective: Our primary objective was to test the novel adenosine A2A/A1 receptor antagonist IDAA-338 in alleviating Parkinsonian symptoms when given as a mono or as…Formulations and Assessments of Intra-nasal noses to brain curcumin delivery using reversible nanoparticles for Parkinsonism treatment: A Preclinical Approach
Objective: Parkinson's disease (PD) is a prevalent neurological illness that is typified by bradykinesia, postural instability, tremor, and stiffness. An increasing body of research suggests…Bidirectional interplay between DBS and cognition in Parkinson’s disease: a systematic review
Objective: To evaluate the evidence regarding (1) deep brain stimulation (DBS) effectiveness in case of postoperative cognitive deterioration, (2) the impact of preoperative cognition on…Motor Impact of Fasting in Parkinson’s Disease Patients: An overview
Objective: To provide a literature overview of fasting impact on motor symptoms in Parkinson disease. Background: Fasting, characterized by voluntary abstinence from food and caloric…Comparative analysis of opicapone and entacapone in the management of motor fluctuations in patients with Parkinson’s disease, from clinical trials to healthcare resource usage
Objective: To assess the differences between two catechol-O-methyltransferase (COMT) inhibitors, opicapone (OPC) and entacapone (ENT). Background: Opicapone and ENT are COMT inhibitors developed as adjunct…Levodopa-Entacapone-Carbidopa Intestinal Gel Treatment In Parkinson’s Disease: A Single-Center Retrospective Chart Study
Objective: The objectives of this chart study were to evaluate adaptations in medication and flow rates and adverse events in patients with Parkinson’s disease (PD)…Repurposing Anti-Gout Medications for the Treatment of Parkinson’s Disease
Objective: To undertake a repurposing drug screen for Parkinson’s disease (PD) and further investigate the mechanism of action of top hits. To assess, in vivo,…Metabolic Regulators of Mitochondrial DNA Release in Cellular Models of PRKN-linked Parkinson’s Disease
Objective: Explore metabolic modulation as a disease-modifying target for inflammation in PRKN-PD Background: The release of mitochondrial DNA (mtDNA) is a well-documented phenotype in PRKN-linked…Age- and Sex-Associated Changes in the Behavior of Neuronal Mitochondria During Healthy Aging
Objective: To determine age-associated changes in the size, density, movement, and dynamics of mitochondria as a function of sex, using microRNA-induced neurons derived from primary…
- « Previous Page
- 1
- …
- 55
- 56
- 57
- 58
- 59
- …
- 181
- Next Page »